SFZN Stock Analysis: Siegfried Holding | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 3.097m CHF | 12M Return: -24.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.41M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Siegfried Holding AG (SFZN) is a Swiss-based contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and finished dosage forms for pharmaceutical clients worldwide. The company operates through two main segments: drug substances, which includes custom API manufacturing and a portfolio of non-exclusive APIs focused on therapeutic areas such as anesthetics, pain and addiction treatment, central nervous system and respiratory diseases, plus pharmaceutical-grade caffeine; and drug products, covering sterile fill-and-finish (vials, ampoules, cartridges, pre-filled syringes), ophthalmics, inhalation capsules, oral solid dosage forms (tablets and capsules), and viral vectors for cell and gene therapies. Founded in 1873 and headquartered in Zofingen, Switzerland, Siegfried offers a broad technology platform spanning chemistry, analytical services, formulation, containment, and cell and gene therapy capabilities.
Within the pharmaceutical CDMO sector, Siegfried serves as an outsourced manufacturing partner to both brand-name drug developers and generic drug producers, allowing clients to access specialized production capacity, regulatory expertise, and technical capabilities without building them in-house. The CDMO model typically involves long-term supply agreements and high regulatory barriers to entry, given the stringent good manufacturing practice (GMP) standards required by health authorities.
- Steriles fill-finish demand expands order pipeline and capacity utilization
- Cell and gene therapy capacity buildout adds high-margin growth vector
- API margin compression persists amid Asian generic competition
| Net Income: 168.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 1.09 > 1.0 |
| NWC/Revenue: 39.46% < 20% (prev 48.88%; Δ -9.42% < -1%) |
| CFO/TA 0.10 > 3% & CFO 221.9m > Net Income 168.7m |
| Net Debt (472.1m) to EBITDA (303.2m): 1.56 < 3 |
| Current Ratio: 2.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.8m) vs 12m ago 906.0% < -2% |
| Gross Margin: 26.66% > 18% (prev 25.42%; Δ 1.24% > 0.5%) |
| Asset Turnover: 64.97% > 50% (prev 66.95%; Δ -1.97% > 0%) |
| Interest Coverage Ratio: 23.86 > 6 (EBIT TTM 208.5m / Interest Expense TTM 8.74m) |
| A: 0.24 (Total Current Assets 1.05b - Total Current Liabilities 524.7m) / Total Assets 2.15b |
| B: 0.54 (Retained Earnings 1.17b / Total Assets 2.15b) |
| C: 0.10 (EBIT TTM 208.5m / Avg Total Assets 2.04b) |
| D: 1.10 (Book Value of Equity 1.13b / Total Liabilities 1.03b) |
| Altman-Z'' = 5.21 = AAA |
| DSRI: 1.20 (Receivables 504.3m/411.4m, Revenue 1.33b/1.29b) |
| GMI: 0.95 (GM 25.42% / 26.66%) |
| AQI: 0.94 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.03 (Revenue 1.33b / 1.29b) |
| TATA: -0.02 (NI 168.7m - CFO 221.9m) / TA 2.15b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at CHF 71.05 with a total of 56,216 shares traded. Over the past week, the price has changed by -2.47%, over one month by +1.65%, over three months by -8.97% and over the past year by -24.67%.
Current recommended Stop Loss: 68.50 (which is 3.6% or 1.3 ATR below the current price).
Siegfried Holding has no consensus analysts rating.
P/E Trailing = 18.4115
P/E Forward = 16.8067
P/S = 2.3326
P/B = 2.7494
P/EG = 1.3475
Revenue TTM = 1.33b CHF
EBIT TTM = 208.5m CHF
EBITDA TTM = 303.2m CHF
Long Term Debt = 375.2m CHF (from longTermDebt, last quarter)
Short Term Debt = 200.0m CHF (from shortTermDebt, last quarter)
Debt = 575.2m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = 472.1m CHF (calculated: Debt 575.2m - CCE 103.1m)
Enterprise Value = 3.57b CHF (3.10b + Debt 575.2m - CCE 103.1m)
Interest Coverage Ratio = 23.86 (Ebit TTM 208.5m / Interest Expense TTM 8.74m)
EV/FCF = 357.9x (Enterprise Value 3.57b / FCF TTM 9.97m)
FCF Yield = 0.28% (FCF TTM 9.97m / Enterprise Value 3.57b)
FCF Margin = 0.75% (FCF TTM 9.97m / Revenue TTM 1.33b)
Net Margin = 12.70% (Net Income TTM 168.7m / Revenue TTM 1.33b)
Gross Margin = 26.66% ((Revenue TTM 1.33b - Cost of Revenue TTM 973.8m) / Revenue TTM)
Gross Margin QoQ = 26.97% (prev 26.31%)
Tobins Q-Ratio = 1.66 (Enterprise Value 3.57b / Total Assets 2.15b)
Interest Expense / Debt = 1.52% (Interest Expense 8.74m / Debt 575.2m)
Taxrate = 19.31% (40.3m / 208.7m)
NOPAT = 168.2m (EBIT 208.5m * (1 - 19.31%))
Current Ratio = 2.00 (Total Current Assets 1.05b / Total Current Liabilities 524.7m)
Debt / Equity = 0.51 (Debt 575.2m / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = 1.56 (Net Debt 472.1m / EBITDA 303.2m)
Debt / FCF = 47.34 (Net Debt 472.1m / FCF TTM 9.97m)
Total Stockholder Equity = 999.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.25% (Net Income 168.7m / Total Assets 2.15b)
RoE = 16.87% (Net Income TTM 168.7m / Total Stockholder Equity 999.5m)
RoCE = 15.16% (EBIT 208.5m / Capital Employed (Equity 999.5m + L.T.Debt 375.2m))
RoIC = 9.54% (NOPAT 168.2m / Invested Capital 1.76b)
WACC = 6.96% (E(3.10b)/V(3.67b) * Re(8.03%) + D(575.2m)/V(3.67b) * Rd(1.52%) * (1-Tc(0.19)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.46 | Cagr: 0.50%
[DCF] Terminal Value 75.44% ; FCFF base≈9.97m ; Y1≈10.0m ; Y5≈10.6m
[DCF] Fair Price = N/A (negative equity: EV 165.0m - Net Debt 472.1m = -307.1m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.99 | Revenue CAGR: 2.10% | SUE: -0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=4.05 | Chg30d=+0.62% | Revisions=+25% | GrowthEPS=+9.8% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=4.65 | Chg30d=+0.28% | Revisions=+25% | GrowthEPS=+14.7% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +40% (up=2, down=0)